Overview

"A Study of a Deuterated Psilocin Analog (CYB003) in Humans With Major Depressive Disorder"

Status:
RECRUITING
Trial end date:
2026-09-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to examine the efficacy, safety, and tolerability of CYB003 compared to matching placebo as adjunctive treatment in participants with MDD.
Phase:
PHASE3
Details
Lead Sponsor:
Cybin IRL Limited
Collaborator:
Worldwide Clinical Trials